Insmed Down on Disappointing Arikayce Results Zacks By Zacks Equity Research
Insmed Down on Disappointing Arikayce Results
Zacks By Zacks Equity Research
r the company announced that its candidate, Arikayce, failed to meet the primary objective in a phase II study (n=90). The candidate is being developed for the treatment of patients suffering from treatment resistant nontuberculous mycobacterial (:NTM) lung infections.
The primary objective of the phase II study was a semi-quantitative measurement of the difference in mycobacterial density on a seven-point scale from baseline to the end of the randomized portion of the study